Spotlight on Europe
Analysis Group’s global health care team contributes to pharmaceutical manufacturers’ product strategies and decision making of major regulatory and health technology assessment (HTA) agencies, payers, physicians, and patients.
Drawing on resources from our offices across North America, Europe, and Asia, including in London, Brussels, and Paris, we provide specialized expertise in health economics and outcomes research (HEOR), epidemiology, market access strategies, pricing, and reimbursement.
In Europe, our experience includes:
- Indirect treatment comparisons to generate comparative-effectiveness evidence and support HTA submissions
- Developing cost-effectiveness models and budget impact models for HTA submissions
- Developing global value dossiers to support launch in multiple countries
- Generating real-world evidence (RWE) using multi-country chart reviews and database analyses
- Developing and validating new patient-reported outcome (PRO) measures and application of PROs in multi-country patient surveys
- Analyzing clinical trial data to support PRO labels
- Conducting safety studies and submitting evidence to regulatory agencies
- Providing market access strategies through market research and collecting insights from payers and providers through advisory board and in-depth interviews
Some examples of our recent European work are highlighted below.
- We developed cost-effectiveness models that resulted in positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of hidradenitis suppurativa and of non-small cell lung cancer (NSCLC).
- The post-authorization safety study we conducted for an antifungal drug led to favorable reviews of our client’s post-marketing programs by both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA).
- At European ISPOR 2017, we organized and presented a symposium on "Evaluating survival benefits in technology appraisals of innovative oncology drugs," in collaboration with Dr. Nicholas Latimer from The University of Sheffield.
- Working with a major global pharmaceutical company, we analyzed historical activity in outcomes-based contracting, comparing trends in the United States and the EU-5 (France, Germany, Italy, Spain, and the United Kingdom). ■